Normal view MARC view ISBD view

Neoadjuvant chemotherapy with Ifosfamide and Cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience

In Medical Oncology
Contributor(s): Parikh PM | Mistry RC | Bakshi AV | Parikh DM | Mazumdar, Alaka T | Deshmukh C | Pathak KA | drvrpai@rediffmail.com | Pai VR.
Material type: materialTypeLabelArticleSeries: Vol 20 Issues 1.Publisher: 2003Description: 1-5.Subject(s): Cancer | Head and neck | Chemotherapy | DDC classification: In: Medical OncologySummary: Advanced head and neck cancer is a major therapeutic problem in India. Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma. In this study, we present our experience with two cycles of ifosfamide and cisplatin in the neoadjuvant setting given to a total of 519 patients. The complete response rate was 20% and the overall response rate was 80%. The treatment was well tolerate, there was no need for dose reduction, and there were no life-threatening side effects. We feel that this high response rate is sufficient to warrant more studies using ifosfamide-based combinations in a neoadjuvant setting for squamous carcinoma of the head and neck.
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR4526

Advanced head and neck cancer is a major therapeutic problem in India. Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma. In this study, we present our experience with two cycles of ifosfamide and cisplatin in the neoadjuvant setting given to a total of 519 patients. The complete response rate was 20% and the overall response rate was 80%. The treatment was well tolerate, there was no need for dose reduction, and there were no life-threatening side effects. We feel that this high response rate is sufficient to warrant more studies using ifosfamide-based combinations in a neoadjuvant setting for squamous carcinoma of the head and neck.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha